globe_newswire · 2026-08-24
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Read the original at globe_newswire ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。